European Pharmaceutical Review

FEBRUARY 27, 2024

Novel biosimilar approval In the same month, the US Food and Drug Administration (FDA) approved Amgen’s Wezlana (ustekinumab-auub) as the first biosimilar to reference blockbuster drug Stelara (ustekinumab). The post Amgen opens its most advanced manufacturing facility to date appeared first on European Pharmaceutical Review.

Biosimilars 105

Biosimilars Pharmaceutical Companies Pharmaceutical Companies Drug Development 105

PharmaShots

JUNE 7, 2023

Our team at PharmaShots has summarized 16 key events of the biosimilar space of May 2023 1. based on change from baseline on a standardized DAS28-CRP which evaluates the severity of RA using clinical and laboratory data Additionally, the company initiates PK study for AVT05 in Jan 2023. 84% vs 64%) & 2yr. (60%

Biosimilars 40

Biosimilars Packaging Diabetes Pharmaceutical Companies 40

pharmaphorum

OCTOBER 13, 2022

ResearchandMarkets also recently published a report , which highlighted only biosimilars as the emerging treatments for osteoporosis. Emerging research and biosimilars. Sandoz recently announced positive clinical trial results from a phase 1/3 into its biosimilar to denosumab.

Biosimilars 98

Biosimilars Communication Pharmaceutical Companies Pharmaceutical Companies 98

Pharmaceutical Technology

MAY 23, 2023

The recent legislative reform proposals put forward by the European Commission (EC) have sparked significant discontent among pharmaceutical companies. This blog explores the key areas of concern for pharmaceutical companies and some of the potential implications of these reforms.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Biosimilars Packaging 52

Express Pharma

OCTOBER 16, 2024

Manufacturing costs in India are also 30 – 35 per cent lower than those in the US and Europe (5), further sweetening the deal for global pharmaceutical companies. Biocon Biologics gained EMA approval to manufacture biosimilar Bevacizumab at its advanced facility in Bengaluru, enhancing its credibility internationally.

Biosimilars 103

Biosimilars Compounding Pharmaceutical Companies Pharmaceutical Companies 103

pharmaphorum

JANUARY 14, 2021

Not so China, and especially not so the lead five European countries – on average European pharmaceutical companies saw a loss of 30% of the interactive time they previously had with healthcare professionals in 2020. Biosimilars accelerate. Focus on customer engagement impact.

Biosimilars 71

Biosimilars Pharmaceutical Companies Pharmaceutical Companies Labelling 71

Express Pharma

SEPTEMBER 3, 2024

Drawing on his experience as an ESG consultant, Sunil Kumar comments that the sustainability journey for pharmaceutical companies, including smaller and MSME pharma clients, has varied widely depending on their size, resources, and initial practices. For example, Shah points out that Biocon’s $1.2

Packaging 111

Packaging Biosimilars Communication Pharmaceutical Companies 111